Methods and compositions for cell-proliferation-related disorders
US-2015240286-A1 · Aug 27, 2015 · US
Therapeutically active compositions and their methods of use
US9512107B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9512107-B2 |
| Application number | US-201615173519-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 3, 2016 |
| Priority date | Jan 6, 2012 |
| Publication date | Dec 6, 2016 |
| Grant date | Dec 6, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound which is or a pharmaceutically acceptable salt or hydrate thereof. 2. The compound of claim 1 , wherein the compound is 3. A pharmaceutical composition comprising a compound of claim 1 , and a pharmaceutically acceptable carrier. 4. A method of treating a cancer characterized by the presence of an IDH2 mutation, wherein the IDH2 mutation results in a new ability of the enzyme to catalyze the NAPH dependent reduction of α ketoglutarate to R(−) 2 hydroxyglutarate in a patient, comprising the step of administering to the patient in need thereof a compound of claim 1 . 5. The method of claim 4 , wherein the IDH2 mutation is an IDH2 R140Q or R172K mutation. 6. The method of claim 4 , wherein the IDH2 mutation is an IDH2 R140Q mutation. 7. The method of claim 4 , wherein the cancer is selected from glioblastoma, myelodysplastic syndrome, myeloproliferative neoplasm, acute myelogenous leukemia, sarcoma, melanoma, non small cell lung cancer, chondrosarcoma, cholangiocarcinomas or angioimmunoblastic non-Hodgkin's lymphoma. 8. The method of claim 4 , wherein the cancer is acute myelogenous leukemia. 9. The method of claim 4 , further comprising administering to the patient in need thereof a second therapeutic agent useful in the treatment of cancer.
Assignees
Inventors
Classifications
specific for leukemia · CPC title
- C07D413/14Primary
containing three or more hetero rings · CPC title
not condensed and containing further heterocyclic rings, e.g. timolol · CPC title
linked by a chain containing hetero atoms as chain links · CPC title
with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9512107B2 cover?
- Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.
- Who is the assignee on this patent?
- Agios Pharmaceuticals Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D413/14. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Dec 06 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).